News >

Pembrolizumab Impresses in Heavily Pretreated Head and Neck Cancer

Jason Harris
Published: Friday, Apr 07, 2017

Joshua M. Bauml, MD

Joshua M. Bauml, MD

Pembrolizumab (Keytruda) showed durable, clinically significant responses in patients with locally advanced head and neck cancer who were refractory to platinum-based chemotherapy and cetuximab (Erbitux), according to results from the single-arm, phase II KEYNOTE-055 study published online in the Journal of Clinical Oncology.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication